Abstract 162P
Background
To evaluate clinical usefulness of hypofractionated radiotherapy (HRT) for pulmonary metastases from hepatocellular carcinoma (HCC) and investigate the prognostic factors affecting treatment outcome.
Methods
From March 2006 to May 2018, 58 patients with less than five pulmonary metastases from HCC who underwent HRT were analyzed retrospectively. Primary endpoint was treatment response rate. Secondary endpoints were progression-free survival, overall survival, prognostic factors affecting treatment outcomes and treatment-related side effects.
Results
The treatment response (complete and partial response) rate was 77.6 %, and the maximum treatment response was presented between 1 to 3 months after completion of HRT. The local control rate was 63.8 %. The median survival time was 16.3 months for all patients. The 1-year and 3-year overall survival rates were 79.3 % and 37.9 %, respectively. The median progression-free survival time was about 5 months and eighty-six percent of the patients (n = 50) showed post-treatment disease progression. Multivariate analysis identified the common prognostic factors for both OS and PFS as the planning target volume and maximal treatment response after HRT. The progression-free survival period was also a prognostic factor for OS in multivariate analysis. The grade 3 and 4 severe toxicities were reported in 4 and 3 patients, respectively.Table:
162P Prognostic factors
OS | PFS | |||||
---|---|---|---|---|---|---|
Median±SD* | p value† | Median±SD* | p value† | |||
Variable | (mo) | UVA | MVA | (mo) | UVA | MVA |
Age | 0.650 | 0.030 | 0.012 | |||
< 60 | 16.2±4.6 | 3.7±3.7 | ||||
≥ 60 | 21.4±7.9 | 4.9±1.3 | ||||
ECOG | 0.097 | 0.401 | ||||
0 | 44.3±17.2 | 8.0±3.0 | ||||
1, 2 | 16.3±4.5 | 3.7±1.3 | ||||
PTV size | 0.017 | 0.003 | 0.027 | 0.003 | ||
< 19 cc | 30.3±8.5 | 5.7±2.0 | ||||
≥ 19 cc | 11.5±2.1 | 3.0±0.3 | ||||
Type I max response | 0.013 | 0.000 | 0.029 | |||
CR+PR | 20.1±4.3 | 5.1±1.6 | ||||
SD+PD | 6.0±1.2 | 1.3±1.1 | ||||
Type II max response | 0.006 | 0.014 | 0.018 | |||
CR+PR+SD | 20.1±3.5 | 5.1±1.3 | ||||
PD | 4.6±1.8 | 1.2±0.1 | ||||
PFS period | 0.001 | 0.003 | ||||
< 5 mon | 10.6±3.5 | |||||
≥ 5 mon | 44.3±11.7 | |||||
Overall | 16.3±4.4 | 4.9±1.2 |
Conclusions
The considerable treatment outcome and acceptable toxicity may indicate clinical usefulness of HRT for patients who have less than five pulmonary metastases from HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract